Search

Your search keyword '"Moslehi, Javid J."' showing total 559 results
Start Over Author "Moslehi, Javid J."
559 results on '"Moslehi, Javid J."'

2. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.

Author

Salem, Joe-Elie, Bretagne, Marie, Abbar, Baptiste, Leonard-Louis, Sarah, Ederhy, Stéphane, Redheuil, Alban, Boussouar, Samia, Nguyen, Lee S, Procureur, Adrien, Stein, Frederic, Fenioux, Charlotte, Devos, Perrine, Gougis, Paul, Dres, Martin, Demoule, Alexandre, Psimaras, Dimitri, Lenglet, Timothee, Maisonobe, Thierry, De Chambrun, Marc Pineton, Hekimian, Guillaume, Straus, Christian, Gonzalez-Bermejo, Jesus, Klatzmann, David, Rigolet, Aude, Guillaume-Jugnot, Perrine, Champtiaux, Nicolas, Benveniste, Olivier, Weiss, Nicolas, Saheb, Samir, Rouvier, Philippe, Plu, Isabelle, Gandjbakhch, Estelle, Kerneis, Mathieu, Hammoudi, Nadjib, Zahr, Noel, Llontop, Claudia, Morelot-Panzini, Capucine, Lehmann, Lorenz, Qin, Juan, Moslehi, Javid J, Rosenzwajg, Michelle, Similowski, Thomas, and Allenbach, Yves

Subjects
Lung, Clinical Research, Rare Diseases, Humans, Myocarditis, Immune Checkpoint Inhibitors, Abatacept, Antineoplastic Agents, Immunological, Myotoxicity, Myositis, Respiratory Muscles, Oncology and Carcinogenesis
Abstract

Immune-checkpoint-inhibitor (ICI)-associated myotoxicity involves the heart (myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are highly fatal. We report the results of a strategy that included identification of individuals with severe ICI myocarditis by also screening for and managing concomitant respiratory muscle involvement with mechanical ventilation, as well as treatment with the CTLA4 fusion protein abatacept and the JAK inhibitor ruxolitinib. Forty cases with definite ICI myocarditis were included with pathologic confirmation of concomitant myositis in the majority of patients. In the first 10 patients, using recommended guidelines, myotoxicity-related fatality occurred in 60%, consistent with historical controls. In the subsequent 30 cases, we instituted systematic screening for respiratory muscle involvement coupled with active ventilation and treatment using ruxolitinib and abatacept. The abatacept dose was adjusted using CD86 receptor occupancy on circulating monocytes. The myotoxicity-related fatality rate was 3.4% (1/30) in these 30 patients versus 60% in the first quartile (P < 0.0001). These clinical results are hypothesis-generating and need further evaluation.SignificanceEarly management of respiratory muscle failure using mechanical ventilation and high-dose abatacept with CD86 receptor occupancy monitoring combined with ruxolitinib may be promising to mitigate high fatality rates in severe ICI myocarditis. See related commentary by Dougan, p. 1040. This article is highlighted in the In This Issue feature, p. 1027.

Published
2023

3. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Author

Fenioux, Charlotte, Abbar, Baptiste, Boussouar, Samia, Bretagne, Marie, Power, John R., Moslehi, Javid J., Gougis, Paul, Amelin, Damien, Dechartres, Agnès, Lehmann, Lorenz H., Courand, Pierre-Yves, Cautela, Jennifer, Alexandre, Joachim, Procureur, Adrien, Rozes, Antoine, Leonard-Louis, Sarah, Qin, Juan, Cheynier, Rémi, Charmeteau-De Muylder, Benedicte, Redheuil, Alban, Tubach, Florence, Cadranel, Jacques, Milon, Audrey, Ederhy, Stéphane, Similowski, Thomas, Johnson, Douglas B., Pizzo, Ian, Catalan, Toniemarie, Benveniste, Olivier, Hayek, Salim S., Allenbach, Yves, Rosenzwajg, Michelle, Dolladille, Charles, and Salem, Joe-Elie

Published
2023
Full Text
View/download PDF

4. T cells specific for α-myosin drive immunotherapy-related myocarditis

Author

Axelrod, Margaret L, Meijers, Wouter C, Screever, Elles M, Qin, Juan, Carroll, Mary Grace, Sun, Xiaopeng, Tannous, Elie, Zhang, Yueli, Sugiura, Ayaka, Taylor, Brandie C, Hanna, Ann, Zhang, Shaoyi, Amancherla, Kaushik, Tai, Warren, Wright, Jordan J, Wei, Spencer C, Opalenik, Susan R, Toren, Abigail L, Rathmell, Jeffrey C, Ferrell, P Brent, Phillips, Elizabeth J, Mallal, Simon, Johnson, Douglas B, Allison, James P, Moslehi, Javid J, and Balko, Justin M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cardiovascular, Heart Disease, Aetiology, 2.1 Biological and endogenous factors, Inflammatory and immune system, Animals, Mice, Autoantigens, CD8-Positive T-Lymphocytes, CTLA-4 Antigen, Immunotherapy, Myocarditis, Ventricular Myosins, General Science & Technology
Abstract

Immune-related adverse events, particularly severe toxicities such as myocarditis, are major challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy1. The pathogenesis of ICI-associated myocarditis (ICI-MC) is poorly understood. Pdcd1-/-Ctla4+/- mice recapitulate clinicopathological features of ICI-MC, including myocardial T cell infiltration2. Here, using single-cell RNA and T cell receptor (TCR) sequencing of cardiac immune infiltrates from Pdcd1-/-Ctla4+/- mice, we identify clonal effector CD8+ T cells as the dominant cell population. Treatment with anti-CD8-depleting, but not anti-CD4-depleting, antibodies improved the survival of Pdcd1-/-Ctla4+/- mice. Adoptive transfer of immune cells from mice with myocarditis induced fatal myocarditis in recipients, which required CD8+ T cells. The cardiac-specific protein α-myosin, which is absent from the thymus3,4, was identified as the cognate antigen source for three major histocompatibility complex class I-restricted TCRs derived from mice with fulminant myocarditis. Peripheral blood T cells from three patients with ICI-MC were expanded by α-myosin peptides. Moreover, these α-myosin-expanded T cells shared TCR clonotypes with diseased heart and skeletal muscle, which indicates that α-myosin may be a clinically important autoantigen in ICI-MC. These studies underscore the crucial role for cytotoxic CD8+ T cells, identify a candidate autoantigen in ICI-MC and yield new insights into the pathogenesis of ICI toxicity.

Published
2022

5. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis

Author

Zhang, Yaohua, Sun, Chengcao, Li, Yajuan, Qin, Juan, Amancherla, Kaushik, Jing, Ying, Hu, Qingsong, Liang, Ke, Zhang, Zhao, Ye, Youqiong, Huang, Lisa A, Nguyen, Tina K, Egranov, Sergey D, Zhao, Zilong, Wu, Andrew, Xi, Yutao, Yao, Jun, Hung, Mien-Chie, Calin, George A, Cheng, Jie, Lim, Bora, Lehmann, Lorenz H, Salem, Joe-Elie, Johnson, Douglas B, Curran, Michael A, Yu, Dihua, Han, Leng, Darabi, Radbod, Yang, Liuqing, Moslehi, Javid J, and Lin, Chunru

Subjects
Cardiovascular, Estrogen, Heart Disease, 5.1 Pharmaceuticals, Aetiology, 2.1 Biological and endogenous factors, Development of treatments and therapeutic interventions, Humans, Female, Male, Mice, Animals, Myocarditis, Immune Checkpoint Inhibitors, Estrogen Receptor beta, Myocytes, Cardiac, Estradiol, Nerve Growth Factors, Biological Sciences, Medical and Health Sciences
Abstract

Immune checkpoint inhibitors (ICIs) have been increasingly used in combination for cancer treatment but are associated with myocarditis. Here, we report that tumor-bearing mice exhibited response to treatment with combinatorial anti-programmed cell death 1 and anti-cytotoxic T lymphocyte antigen-4 antibodies but also presented with cardiovascular toxicities observed clinically with ICI therapy, including myocarditis and arrhythmia. Female mice were preferentially affected with myocarditis compared to male mice, consistent with a previously described genetic model of ICI myocarditis and emerging clinical data. Mechanistically, myocardial tissue from ICI-treated mice, the genetic mouse model, and human heart tissue from affected patients with ICI myocarditis all exhibited down-regulation of MANF (mesencephalic astrocyte-derived neurotrophic factor) and HSPA5 (heat shock 70-kDa protein 5) in the heart; this down-regulation was particularly notable in female mice. ICI myocarditis was amplified by heart-specific genetic deletion of mouse Manf and was attenuated by administration of recombinant MANF protein, suggesting a causal role. Ironically, both MANF and HSPA5 were transcriptionally induced by liganded estrogen receptor β and inhibited by androgen receptor. However, ICI treatment reduced serum estradiol concentration to a greater extent in female compared to male mice. Treatment with an estrogen receptor β-specific agonist and androgen depletion therapy attenuated ICI-associated cardiac effects. Together, our data suggest that ICI treatment inhibits estradiol-dependent expression of MANF/HSPA5 in the heart, curtailing the cardiomyocyte response to immune injury. This endocrine-cardiac-immune pathway offers new insights into the mechanisms of sex differences in cardiac disease and may offer treatment strategies for ICI myocarditis.

Published
2022

7. Publisher Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Author

Fenioux, Charlotte, Abbar, Baptiste, Boussouar, Samia, Bretagne, Marie, Power, John R., Moslehi, Javid J., Gougis, Paul, Amelin, Damien, Dechartres, Agnès, Lehmann, Lorenz H., Courand, Pierre-Yves, Cautela, Jennifer, Alexandre, Joachim, Procureur, Adrien, Rozes, Antoine, Leonard-Louis, Sarah, Qin, Juan, Cheynier, Rémi, Charmeteau-De Muylder, Benedicte, Redheuil, Alban, Tubach, Florence, Cadranel, Jacques, Milon, Audrey, Ederhy, Stéphane, Similowski, Thomas, Johnson, Douglas B., Pizzo, Ian, Catalan, Toniemarie, Benveniste, Olivier, Hayek, Salim S., Allenbach, Yves, Rosenzwajg, Michelle, Dolladille, Charles, and Salem, Joe-Elie

Published
2024
Full Text
View/download PDF

8. Survivorship, Version 1.2021.

Author

Tevaarwerk, Amye, Denlinger, Crystal S, Sanft, Tara, Ansbaugh, Shannon M, Armenian, Saro, Baker, K Scott, Broderick, Gregory, Day, Andrew, Demark-Wahnefried, Wendy, Dickinson, Kristin, Friedman, Debra L, Ganz, Patricia, Goldman, Mindy, Henry, Norah Lynn, Hill-Kayser, Christine, Hudson, Melissa, Khakpour, Nazanin, Koura, Divya, McDonough, Allison L, Melisko, Michelle, Mooney, Kathi, Moore, Halle CF, Moryl, Natalie, Moslehi, Javid J, O'Connor, Tracey, Overholser, Linda, Paskett, Electra D, Patel, Chirayu, Peterson, Lindsay, Pirl, William, Rodriguez, M Alma, Ruddy, Kathryn J, Schapira, Lidia, Shockney, Lillie, Smith, Sophia, Syrjala, Karen L, Zee, Phyllis, McMillian, Nicole R, and Freedman-Cass, Deborah A

Subjects
Health Services and Systems, Nursing, Health Sciences, Cancer, Rehabilitation, Prevention, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, Adult, Cancer Survivors, Humans, Mass Screening, Neoplasms, Survivors, Survivorship, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

The NCCN Guidelines for Survivorship are intended to help healthcare professionals working with cancer survivors to ensure that each survivor's complex and varied needs are addressed. The Guidelines provide screening, evaluation, and treatment recommendations for consequences of adult-onset cancer and its treatment; recommendations to help promote healthful lifestyle behaviors, weight management, and immunizations in survivors; and a framework for care coordination. This article summarizes the recommendations regarding employment and return to work for cancer survivors that were added in the 2021 version of the NCCN Guidelines.

Published
2021

9. Author Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Author

Fenioux, Charlotte, Abbar, Baptiste, Boussouar, Samia, Bretagne, Marie, Power, John R., Moslehi, Javid J., Gougis, Paul, Amelin, Damien, Dechartres, Agnès, Lehmann, Lorenz H., Courand, Pierre-Yves, Cautela, Jennifer, Alexandre, Joachim, Procureur, Adrien, Rozes, Antoine, Leonard-Louis, Sarah, Qin, Juan, Cheynier, Rémi, Charmeteau-De Muylder, Benedicte, Redheuil, Alban, Tubach, Florence, Cadranel, Jacques, Milon, Audrey, Ederhy, Stéphane, Similowski, Thomas, Johnson, Douglas B., Pizzo, Ian, Catalan, Toniemarie, Benveniste, Olivier, Hayek, Salim S., Allenbach, Yves, Rosenzwajg, Michelle, Dolladille, Charles, and Salem, Joe-Elie

Published
2023
Full Text
View/download PDF

10. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.

Author

Zhang, Lili, Awadalla, Magid, Mahmood, Syed S, Nohria, Anju, Hassan, Malek Z O, Thuny, Franck, Zlotoff, Daniel A, Murphy, Sean P, Stone, James R, Golden, Doll Lauren Alexandra, Alvi, Raza M, Rokicki, Adam, Jones-O'Connor, Maeve, Cohen, Justine V, Heinzerling, Lucie M, Mulligan, Connor, Armanious, Merna, Barac, Ana, Forrestal, Brian J, Sullivan, Ryan J, Kwong, Raymond Y, Yang, Eric H, Damrongwatanasuk, Rongras, Chen, Carol L, Gupta, Dipti, Kirchberger, Michael C, Moslehi, Javid J, Coelho-Filho, Otavio R, Ganatra, Sarju, Rizvi, Muhammad A, Sahni, Gagan, Tocchetti, Carlo G, Mercurio, Valentina, Mahmoudi, Michael, Lawrence, Donald P, Reynolds, Kerry L, Weinsaft, Jonathan W, Baksi, A John, Ederhy, Stephane, Groarke, John D, Lyon, Alexander R, Fradley, Michael G, Thavendiranathan, Paaladinesh, and Neilan, Tomas G

Abstract

Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI). Sparse data exist on the use of cardiovascular magnetic resonance (CMR) in ICI-associated myocarditis. In this study, the CMR characteristics and the association between CMR features and cardiovascular events among patients with ICI-associated myocarditis are presented.From an international registry of patients with ICI-associated myocarditis, clinical, CMR, and histopathological findings were collected. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block. In 103 patients diagnosed with ICI-associated myocarditis who had a CMR, the mean left ventricular ejection fraction (LVEF) was 50%, and 61% of patients had an LVEF ≥50%. Late gadolinium enhancement (LGE) was present in 48% overall, 55% of the reduced EF, and 43% of the preserved EF cohort. Elevated T2-weighted short tau inversion recovery (STIR) was present in 28% overall, 30% of the reduced EF, and 26% of the preserved EF cohort. The presence of LGE increased from 21.6%, when CMR was performed within 4 days of admission to 72.0% when CMR was performed on Day 4 of admission or later. Fifty-six patients had cardiac pathology. Late gadolinium enhancement was present in 35% of patients with pathological fibrosis and elevated T2-weighted STIR signal was present in 26% with a lymphocytic infiltration. Forty-one patients (40%) had MACE over a follow-up time of 5 months. The presence of LGE, LGE pattern, or elevated T2-weighted STIR were not associated with MACE.These data suggest caution in reliance on LGE or a qualitative T2-STIR-only approach for the exclusion of ICI-associated myocarditis.

Published
2020

15. Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database

Author

Nguyen, Lee S., Cooper, Leslie T., Kerneis, Mathieu, Funck-Brentano, Christian, Silvain, Johanne, Brechot, Nicolas, Hekimian, Guillaume, Ammirati, Enrico, Ben M’Barek, Badr, Redheuil, Alban, Gandjbakhch, Estelle, Bihan, Kevin, Lebrun-Vignes, Bénédicte, Ederhy, Stephane, Dolladille, Charles, Moslehi, Javid J., and Salem, Joe-Elie

Published
2022
Full Text
View/download PDF

18. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells

Author

Sharma, Arun, Burridge, Paul W, McKeithan, Wesley L, Serrano, Ricardo, Shukla, Praveen, Sayed, Nazish, Churko, Jared M, Kitani, Tomoya, Wu, Haodi, Holmström, Alexandra, Matsa, Elena, Zhang, Yuan, Kumar, Anusha, Fan, Alice C, Del Álamo, Juan C, Wu, Sean M, Moslehi, Javid J, Mercola, Mark, and Wu, Joseph C

Subjects
Medical Physiology, Biomedical and Clinical Sciences, Stem Cell Research - Induced Pluripotent Stem Cell - Human, Stem Cell Research, Clinical Research, Cardiovascular, Stem Cell Research - Induced Pluripotent Stem Cell, Heart Disease, 2.1 Biological and endogenous factors, Good Health and Well Being, Biomarkers, Cardiotoxicity, Fibroblasts, High-Throughput Screening Assays, Humans, Induced Pluripotent Stem Cells, Insulin, Insulin-Like Growth Factor I, Models, Biological, Myocytes, Cardiac, Phosphorylation, Protein Kinase Inhibitors, Sarcomeres, Signal Transduction, Vascular Endothelial Growth Factor Receptor-2, Biological Sciences, Medical and Health Sciences, Medical biotechnology, Biomedical engineering
Abstract

Tyrosine kinase inhibitors (TKIs), despite their efficacy as anticancer therapeutics, are associated with cardiovascular side effects ranging from induced arrhythmias to heart failure. We used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), generated from 11 healthy individuals and 2 patients receiving cancer treatment, to screen U.S. Food and Drug Administration-approved TKIs for cardiotoxicities by measuring alterations in cardiomyocyte viability, contractility, electrophysiology, calcium handling, and signaling. With these data, we generated a "cardiac safety index" to reflect the cardiotoxicities of existing TKIs. TKIs with low cardiac safety indices exhibit cardiotoxicity in patients. We also derived endothelial cells (hiPSC-ECs) and cardiac fibroblasts (hiPSC-CFs) to examine cell type-specific cardiotoxicities. Using high-throughput screening, we determined that vascular endothelial growth factor receptor 2 (VEGFR2)/platelet-derived growth factor receptor (PDGFR)-inhibiting TKIs caused cardiotoxicity in hiPSC-CMs, hiPSC-ECs, and hiPSC-CFs. With phosphoprotein analysis, we determined that VEGFR2/PDGFR-inhibiting TKIs led to a compensatory increase in cardioprotective insulin and insulin-like growth factor (IGF) signaling in hiPSC-CMs. Up-regulating cardioprotective signaling with exogenous insulin or IGF1 improved hiPSC-CM viability during cotreatment with cardiotoxic VEGFR2/PDGFR-inhibiting TKIs. Thus, hiPSC-CMs can be used to screen for cardiovascular toxicities associated with anticancer TKIs, and the results correlate with clinical phenotypes. This approach provides unexpected insights, as illustrated by our finding that toxicity can be alleviated via cardioprotective insulin/IGF signaling.

Published
2017

23. Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation.

Author

Moslehi, Javid J.

Subjects
*SOMATIC mutation, *EPIDERMAL growth factor receptors, *VASCULAR endothelial growth factors, *CHRONIC myeloid leukemia, *IMMUNE checkpoint inhibitors, *PROSTATE cancer, *CARDIOVASCULAR diseases
Abstract

Cardio-oncology has emerged as a new cardiovascular subspecialty in the past 20 years. Older chemotherapies and radiation were known to be cardiotoxic, but the hope was that targeted therapies would reduce these toxicities. However, it was discovered that certain targeted cancer therapies, such as trastuzumab, can cause cardiomyopathy. With the increasing number of oncological therapies being introduced, cardio-oncology has become a new clinical frontier. It also offers a platform for further understanding cardiovascular diseases and developing new treatments. [Extracted from the article]

Published
2024
Full Text
View/download PDF

24. Cardiovascular Toxicities Associated With Ibrutinib

Author

Salem, Joe-Elie, Manouchehri, Ali, Bretagne, Marie, Lebrun-Vignes, Bénédicte, Groarke, John D., Johnson, Douglas B., Yang, Tao, Reddy, Nishitha M., Funck-Brentano, Christian, Brown, Jennifer R., Roden, Dan M., and Moslehi, Javid J.

Published
2019
Full Text
View/download PDF

28. CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis

Author

Régnier, Paul, primary, Le Joncour, Alexandre, additional, Maciejewski-Duval, Anna, additional, Darrasse-Jèze, Guillaume, additional, Dolladille, Charles, additional, Meijers, Wouter C., additional, Bastarache, Lisa, additional, Fouret, Pierre, additional, Bruneval, Patrick, additional, Arbaretaz, Floriane, additional, Sayetta, Célia, additional, Márquez, Ana, additional, Rosenzwajg, Michelle, additional, Klatzmann, David, additional, Cacoub, Patrice, additional, Moslehi, Javid J., additional, Salem, Joe-Elie, additional, and Saadoun, David, additional

Published
2023
Full Text
View/download PDF

30. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Author

Mahmood, Syed S., Fradley, Michael G., Cohen, Justine V., Nohria, Anju, Reynolds, Kerry L., Heinzerling, Lucie M., Sullivan, Ryan J., Damrongwatanasuk, Rongras, Chen, Carol L., Gupta, Dipti, Kirchberger, Michael C., Awadalla, Magid, Hassan, Malek Z.O., Moslehi, Javid J., Shah, Sachin P., Ganatra, Sarju, Thavendiranathan, Paaladinesh, Lawrence, Donald P., Groarke, John D., and Neilan, Tomas G.

Published
2018
Full Text
View/download PDF

32. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Author

Johnson, Douglas B., McDonnell, Wyatt J., Gonzalez-Ericsson, Paula I., Al-Rohil, Rami N., Mobley, Bret C., Salem, Joe-Elie, Wang, Daniel Y., Sanchez, Violeta, Wang, Yu, Chastain, Cody A., Barker, Kristi, Liang, Yan, Warren, Sarah, Beechem, Joseph M., Menzies, Alexander M., Tio, Martin, Long, Georgina V., Cohen, Justine V., Guidon, Amanda C., O’Hare, Méabh, Chandra, Sunandana, Chowdhary, Akansha, Lebrun-Vignes, Bénédicte, Goldinger, Simone M., Rushing, Elisabeth J., Buchbinder, Elizabeth I., Mallal, Simon A., Shi, Chanjuan, Xu, Yaomin, Moslehi, Javid J., Sanders, Melinda E., Sosman, Jeffrey A., and Balko, Justin M.

Published
2019
Full Text
View/download PDF

33. Supplementary Methods from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

Author

Salem, Joe-Elie, primary, Bretagne, Marie, primary, Abbar, Baptiste, primary, Leonard-Louis, Sarah, primary, Ederhy, Stéphane, primary, Redheuil, Alban, primary, Boussouar, Samia, primary, Nguyen, Lee S., primary, Procureur, Adrien, primary, Stein, Frederic, primary, Fenioux, Charlotte, primary, Devos, Perrine, primary, Gougis, Paul, primary, Dres, Martin, primary, Demoule, Alexandre, primary, Psimaras, Dimitri, primary, Lenglet, Timothee, primary, Maisonobe, Thierry, primary, De Chambrun, Marc Pineton, primary, Hekimian, Guillaume, primary, Straus, Christian, primary, Gonzalez-Bermejo, Jesus, primary, Klatzmann, David, primary, Rigolet, Aude, primary, Guillaume-Jugnot, Perrine, primary, Champtiaux, Nicolas, primary, Benveniste, Olivier, primary, Weiss, Nicolas, primary, Saheb, Samir, primary, Rouvier, Philippe, primary, Plu, Isabelle, primary, Gandjbakhch, Estelle, primary, Kerneis, Mathieu, primary, Hammoudi, Nadjib, primary, Zahr, Noel, primary, Llontop, Claudia, primary, Morelot-Panzini, Capucine, primary, Lehmann, Lorenz, primary, Qin, Juan, primary, Moslehi, Javid J., primary, Rosenzwajg, Michelle, primary, Similowski, Thomas, primary, and Allenbach, Yves, primary

Published
2023
Full Text
View/download PDF

34. Figure S2 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

Author

Salem, Joe-Elie, primary, Bretagne, Marie, primary, Abbar, Baptiste, primary, Leonard-Louis, Sarah, primary, Ederhy, Stéphane, primary, Redheuil, Alban, primary, Boussouar, Samia, primary, Nguyen, Lee S., primary, Procureur, Adrien, primary, Stein, Frederic, primary, Fenioux, Charlotte, primary, Devos, Perrine, primary, Gougis, Paul, primary, Dres, Martin, primary, Demoule, Alexandre, primary, Psimaras, Dimitri, primary, Lenglet, Timothee, primary, Maisonobe, Thierry, primary, De Chambrun, Marc Pineton, primary, Hekimian, Guillaume, primary, Straus, Christian, primary, Gonzalez-Bermejo, Jesus, primary, Klatzmann, David, primary, Rigolet, Aude, primary, Guillaume-Jugnot, Perrine, primary, Champtiaux, Nicolas, primary, Benveniste, Olivier, primary, Weiss, Nicolas, primary, Saheb, Samir, primary, Rouvier, Philippe, primary, Plu, Isabelle, primary, Gandjbakhch, Estelle, primary, Kerneis, Mathieu, primary, Hammoudi, Nadjib, primary, Zahr, Noel, primary, Llontop, Claudia, primary, Morelot-Panzini, Capucine, primary, Lehmann, Lorenz, primary, Qin, Juan, primary, Moslehi, Javid J., primary, Rosenzwajg, Michelle, primary, Similowski, Thomas, primary, and Allenbach, Yves, primary

Published
2023
Full Text
View/download PDF

35. Table S3 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

Author

Salem, Joe-Elie, primary, Bretagne, Marie, primary, Abbar, Baptiste, primary, Leonard-Louis, Sarah, primary, Ederhy, Stéphane, primary, Redheuil, Alban, primary, Boussouar, Samia, primary, Nguyen, Lee S., primary, Procureur, Adrien, primary, Stein, Frederic, primary, Fenioux, Charlotte, primary, Devos, Perrine, primary, Gougis, Paul, primary, Dres, Martin, primary, Demoule, Alexandre, primary, Psimaras, Dimitri, primary, Lenglet, Timothee, primary, Maisonobe, Thierry, primary, De Chambrun, Marc Pineton, primary, Hekimian, Guillaume, primary, Straus, Christian, primary, Gonzalez-Bermejo, Jesus, primary, Klatzmann, David, primary, Rigolet, Aude, primary, Guillaume-Jugnot, Perrine, primary, Champtiaux, Nicolas, primary, Benveniste, Olivier, primary, Weiss, Nicolas, primary, Saheb, Samir, primary, Rouvier, Philippe, primary, Plu, Isabelle, primary, Gandjbakhch, Estelle, primary, Kerneis, Mathieu, primary, Hammoudi, Nadjib, primary, Zahr, Noel, primary, Llontop, Claudia, primary, Morelot-Panzini, Capucine, primary, Lehmann, Lorenz, primary, Qin, Juan, primary, Moslehi, Javid J., primary, Rosenzwajg, Michelle, primary, Similowski, Thomas, primary, and Allenbach, Yves, primary

Published
2023
Full Text
View/download PDF

36. Data from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

Author

Salem, Joe-Elie, primary, Bretagne, Marie, primary, Abbar, Baptiste, primary, Leonard-Louis, Sarah, primary, Ederhy, Stéphane, primary, Redheuil, Alban, primary, Boussouar, Samia, primary, Nguyen, Lee S., primary, Procureur, Adrien, primary, Stein, Frederic, primary, Fenioux, Charlotte, primary, Devos, Perrine, primary, Gougis, Paul, primary, Dres, Martin, primary, Demoule, Alexandre, primary, Psimaras, Dimitri, primary, Lenglet, Timothee, primary, Maisonobe, Thierry, primary, De Chambrun, Marc Pineton, primary, Hekimian, Guillaume, primary, Straus, Christian, primary, Gonzalez-Bermejo, Jesus, primary, Klatzmann, David, primary, Rigolet, Aude, primary, Guillaume-Jugnot, Perrine, primary, Champtiaux, Nicolas, primary, Benveniste, Olivier, primary, Weiss, Nicolas, primary, Saheb, Samir, primary, Rouvier, Philippe, primary, Plu, Isabelle, primary, Gandjbakhch, Estelle, primary, Kerneis, Mathieu, primary, Hammoudi, Nadjib, primary, Zahr, Noel, primary, Llontop, Claudia, primary, Morelot-Panzini, Capucine, primary, Lehmann, Lorenz, primary, Qin, Juan, primary, Moslehi, Javid J., primary, Rosenzwajg, Michelle, primary, Similowski, Thomas, primary, and Allenbach, Yves, primary

Published
2023
Full Text
View/download PDF

41. Data from A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

Author

Wei, Spencer C., primary, Meijers, Wouter C., primary, Axelrod, Margaret L., primary, Anang, Nana-Ama A.S., primary, Screever, Elles M., primary, Wescott, Elizabeth C., primary, Johnson, Douglas B., primary, Whitley, Elizabeth, primary, Lehmann, Lorenz, primary, Courand, Pierre-Yves, primary, Mancuso, James J., primary, Himmel, Lauren E., primary, Lebrun-Vignes, Benedicte, primary, Wleklinski, Matthew J., primary, Knollmann, Bjorn C., primary, Srinivasan, Jayashree, primary, Li, Yu, primary, Atolagbe, Oluwatomisin T., primary, Rao, Xiayu, primary, Zhao, Yang, primary, Wang, Jing, primary, Ehrlich, Lauren I.R., primary, Sharma, Padmanee, primary, Salem, Joe-Elie, primary, Balko, Justin M., primary, Moslehi, Javid J., primary, and Allison, James P., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Data from A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

Author

Wei, Spencer C., primary, Meijers, Wouter C., primary, Axelrod, Margaret L., primary, Anang, Nana-Ama A.S., primary, Screever, Elles M., primary, Wescott, Elizabeth C., primary, Johnson, Douglas B., primary, Whitley, Elizabeth, primary, Lehmann, Lorenz, primary, Courand, Pierre-Yves, primary, Mancuso, James J., primary, Himmel, Lauren E., primary, Lebrun-Vignes, Benedicte, primary, Wleklinski, Matthew J., primary, Knollmann, Bjorn C., primary, Srinivasan, Jayashree, primary, Li, Yu, primary, Atolagbe, Oluwatomisin T., primary, Rao, Xiayu, primary, Zhao, Yang, primary, Wang, Jing, primary, Ehrlich, Lauren I.R., primary, Sharma, Padmanee, primary, Salem, Joe-Elie, primary, Balko, Justin M., primary, Moslehi, Javid J., primary, and Allison, James P., primary

Published
2023
Full Text
View/download PDF

43. Abstract 14843: Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Associated Myocarditis

Author

Power, John R, Alexandre, Joachim, Choudhary, Arrush, ozbay, benay, Palaskas, Nicolas L, Lehmann, Lorenz H, Finke, Daniel, Cautela, Jennifer, Thuny, Franck, Tamura, Yuichi, Hayek, Salim S, Azam, Tariq U, Asnani, Aarti, Mehegan, Tyler, Aras, Mandar A, Baik, Alan H, Gilstrap, Lauren, Laufer-Perl, Michal, Arangalage, Dimitri, Ewer, Steven, Martini, Matthew, Nowatzke, Joseph, Orimoloye, Olusola A, Brinkley, Douglas M, Meijers, Wouter C, Fenioux, Charlotte, EDERHY, Stephane, Moslehi, Javid J, and Salem, Joe-elie

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results